Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Nivolumab for MDSC Depletion in NSCLC
NCT03302247Phase 2Terminated
- Sponsor
- Fox Chase Cancer Center
- Start
- Jan 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine in non-small cell lung cancer (NSCLC), sponsored by Fox Chase Cancer Center. Started Jan 2018; status: terminated.
02
Drugs
gemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03302247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03302247.